La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Mesh.i » - entrée « Selegiline »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Selective Estrogen Receptor Modulators < Selegiline < Self Care  Facettes :

List of bibliographic references indexed by Selegiline

Number of relevant bibliographic references: 22.
[0-20] [0 - 20][0 - 22][20-21][20-40]
Ident.Authors (with country if any)Title
001494 (2012) E. W. Tsang [Canada] ; C. Hamani [Canada] ; E. Moro [Canada] ; F. Mazzella [Canada] ; U. Saha [Canada] ; A. M. Lozano [Canada] ; M. Hodaie [Canada] ; R. Chuang [Canada] ; T. Steeves [Canada] ; S. Y. Lim [Canada, Malaisie] ; B. Neagu [Canada] ; R. Chen [Canada]Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease
001D77 (2009) E R Dorsey [États-Unis] ; J P Thompson ; E J Dayoub ; B. George ; L A Saubermann ; R G HollowaySelegiline shortage: Causes and costs of a generic drug shortage.
001F01 (2009) Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis]A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts
002228 (2008) Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Paula A. Rochon [Canada] ; Caroline M. Tanner [États-Unis] ; Gary Naglie [Canada] ; Anthony E. Lang [Canada]Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial
002956 (2005) C. Marras [Canada] ; M P Mcdermott ; P A Rochon ; C M Tanner ; G. Naglie ; A. Rudolph ; A E LangSurvival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
003453 (2000) Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada]R -(−)-Deprenyl Inhibits Monocytic THP-1 Cell Neurotoxicity Independently of Monoamine Oxidase Inhibition
003741 (1999) Line Ste-Marie [Canada] ; Luc Vachon [Canada] ; Chantal Bémeur [Canada] ; Jean Lambert [Canada] ; Jane Montgomery [Canada]Local striatal infusion of MPP+ does not result in increased hydroxylation after systemic administration of 4-hydroxybenzoate
003962 (1998) D. B. Shoulson [États-Unis]Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
003D02 (1996) W G Tatton [Canada] ; J S Wadia ; W Y Ju ; R M Chalmers-Redman ; N A Tatton(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
004125 (1994) D B Calne [Canada]Early idiopathic parkinsonism: initiation and optimization of treatment.
004157 (1994) M. D. Berry [Canada] ; A. V. Juorio [Canada] ; I. A. Paterson [Canada]Possible mechanisms of action of (−)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders
004310 (1993) W G Tatton [Canada]Selegiline can mediate neuronal rescue rather than neuronal protection.
004477 (1992) W R MartinDrug information discrepancy.
004549 (1992) James W. Schulzer [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada]The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic
004653 (1992) P. Vezina [Canada] ; E. Mohr ; D. GrimesDeprenyl in Parkinson's disease : mechanisms, neuroprotective effect, indications and adverse effects
004677 (1991) J D Grimes [Canada]Deprenyl: the exciting possibility of protective effect.
004754 (1991) G. J. Tatton [Canada] ; C. E. Greenwood [Canada]Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
004828 (1991) O. S. Kofman [Canada]Deprenyl : protective vs. symptomatic effect
004A20 (1989) I. Shoulson [États-Unis]Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group.
004B26 (1989) J. K. Tsui ; S. Ross ; K. Poulin ; J. Douglas ; D. Postnikoff ; S. Calne ; W. Woodward ; D. B. CalneThe effect of dietary protein on the efficacy of L-dopa: a double-blind study
004C53 (1988) J. D. Grimes ; M. N. Hassan ; J. H. ThakarPrevention of progression of Parkinson's disease with antioxidative therapy

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Selegiline" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Selegiline" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Selegiline
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022